1488 A multicenter phase 2 trial of lifileucel plus pembrolizumab in patients with checkpoint inhibitor-naive metastatic NSCLC: updated results

Ben Creelan, Kai He, Edward B. Garon, Jason Chesney, Sylvia Lee, Jorge J. Nieva, Adrian G. Sacher, Friedrich Graf Finckenstein, Brian Gastman, Jeffrey Chou, Rana Fiaz, Melissa Catlett, Guang Chen, Adam Schoenfeld2024 · DOI

Abstract

Resistance to frontline immune checkpoint inhibitor (ICI) ± chemotherapy presents a challenge in the treatment of metastatic non-small cell lung cancer (NSCLC). Tumor-infiltrating lymphocyte (TIL) cell therapy with lifileucel alone demonstrated an objective response rate (ORR) of 21% in patients with refractory metastatic NSCLC previously treated with an ICI. Integration of TIL cell therapy in frontline regimens may improve long-term outcomes in NSCLC. We report updated efficacy and safety results for lifileucel combined with pembrolizumab in patients with ICI-naive metastatic NSCLC.

TL;DR

This study demonstrates that combining lifileucel (a tumor-infiltrating lymphocyte therapy) with pembrolizumab (an immune checkpoint inhibitor) yields a high and durable response rate in patients with advanced lung cancer who have not previously received immunotherapy. Most notably, the combination showed significant efficacy even in "cold" tumors (PD-L1 negative) that typically respond poorly to standard treatments.

What Problem Does This Paper Address?

Metastatic non-small cell lung cancer (NSCLC) remains a major clinical challenge. While frontline treatment with immune checkpoint inhibitors (ICIs) like pembrolizumab—with or without chemotherapy—has improved survival, many patients either do not respond or eventually develop resistance.

Previous studies showed that lifileucel, a cell therapy made from a patient's own tumor-infiltrating lymphocytes (TILs), could help patients whose cancer had already failed ICI therapy. This paper investigates moving TIL therapy to the frontline: by combining lifileucel with pembrolizumab in ICI-naive patients, researchers aimed to achieve deeper and more lasting responses than standard care alone.

Methods

The study, part of the IOV-COM-202 (NCT03645928) phase 2 trial, utilized a specific multi-step protocol for Cohort 3A:

  1. Priming: Patients received one dose of pembrolizumab.
  2. Preparation: Patients underwent nonmyeloablative lymphodepletion (cyclophosphamide and fludarabine).
  3. Infusion: A single infusion of lifileucel (autologous TILs).
  4. Boosting: Patients received up to six doses of high-dose interleukin-2 (IL-2).
  5. Maintenance: Pembrolizumab was continued for up to two years.

Key Results

As of August 12, 2024, 22 patients had been infused with lifileucel. The population was predominantly "hard-to-treat": 77.3% had a PD-L1 tumor proportion score (TPS) of <1 (negative), and 63.6% were EGFR wild-type (wt).

In the EGFR-wt subgroup, the ORR was 64.3% (9/14 patients). Notably, in patients who were both EGFR-wt and PD-L1 negative, the ORR was 54.5% (6/11). Five patients had durable and ongoing responses at last follow-up, including 3 patients with PD-L1–negative status.

Figure 1: Swimmer plot showing duration of response and PD-L1 status for patients treated with lifileucel plus pembrolizumab. Ongoing responses are indicated by blue triangles.

For the EGFR-mutation post-TKI subgroup, the ORR was 12.5%. Safety profiles were consistent with underlying disease and known profiles of the components; common Grade 3+ nonhematologic adverse events included hypoxia (54.5%) and febrile neutropenia (45.5%).

Key Insights and Ideas

  • Overcoming "Cold" Tumors: The most striking insight is the efficacy in PD-L1 negative patients. Usually, these "cold" tumors are less visible to the immune system and respond poorly to ICIs. Here, the TILs seem to provide the necessary "recognition" that the endogenous immune system lacked.
  • Durability is King: In the EGFR-wt subgroup, the median Duration of Response (DOR) was not reached. This suggests that once a response is achieved, it tends to be very stable, with several patients remaining in response for over two years.
  • Timing Matters: The 64.3% ORR in the frontline EGFR-wt group is substantially higher than the 21% ORR previously seen when lifileucel was used as a later-line therapy. This suggests that TIL therapy may be more effective before the immune system is exhausted by multiple prior lines of treatment.

Limitations and Future Work

The primary limitation is the small sample size (N=22), which requires validation in larger cohorts. Additionally, the complexity of the regimen—requiring surgical resection for TIL manufacturing, lymphodepletion, and hospitalization for IL-2—remains a barrier to widespread adoption compared to "off-the-shelf" drugs. Future work will focus on confirming these results in larger Phase 3 trials and exploring whether this combination can eventually replace or augment chemotherapy in the frontline setting for metastatic NSCLC.

Summary updated

Abstract

<h3>Background</h3> Resistance to frontline immune checkpoint inhibitor (ICI) ± chemotherapy presents a challenge in the treatment of metastatic non-small cell lung cancer (NSCLC). Tumor-infiltrating lymphocyte (TIL) cell therapy with lifileucel alone demonstrated an objective response rate (ORR) of 21% in patients with refractory metastatic NSCLC previously treated with an ICI. Integration of TIL cell therapy in frontline regimens may improve long-term outcomes in NSCLC. We report updated efficacy and safety results for lifileucel combined with pembrolizumab in patients with ICI-naive metastatic NSCLC. <h3>Methods</h3> IOV-COM-202 (NCT03645928) is a global, phase 2, multicenter, multicohort, open-label study. Cohort 3A has enrolled patients with ICI-naive advanced or metastatic NSCLC with disease progression, ≥1 resectable lesion for lifileucel manufacturing, and ≥1 evaluable lesion (by RECIST v1.1). Patients received nonmyeloablative lymphodepletion (cyclophosphamide and fludarabine), followed by a single lifileucel infusion, and ≤6 doses of high-dose interleukin-2 (IL-2). Pembrolizumab was administered once before lymphodepletion and continued after lifileucel up to 2 years. Primary endpoints were ORR and safety (incidence of grade ≥3 TEAEs). <h3>Results</h3> As of August 12, 2024, 22 patients had been infused with lifileucel. Patients had a median age of 57 years (range, 30–69) and a median of 1 (range, 0–4) lines of prior systemic therapy. PD-L1 tumor proportion score was &lt;1 in 77.3% (n=17), tumor <i>EGFR</i> status was wild-type (wt) in 63.6% (n=14). Common anatomic sites of tumor resection were lung (45.5%) and lymph node (22.7%). Median lifileucel dose was 22.9×10<sup>9</sup> cells. At a median follow-up of 25.6 months, the ORR (95% CI) in the <i>EGFR</i>-wt subgroup of interest for further studies was 64.3% (35.1%–87.2%). Median DOR in this subgroup was not reached (NR; 95% CI, 3.7 months–NR). Six responses occurred in 11 patients with <i>EGFR</i>-wt PD-L1–negative disease (54.5%). Five patients had durable and ongoing responses at last follow-up, including 3 patients with PD-L1–negative status (figure 1). For the <i>EGFR</i>-mutation post-TKI (n=8) subgroup, the ORR was 12.5%. TEAEs were consistent with underlying disease and known profiles of pembrolizumab, nonmyeloablative lymphodepletion, and IL-2. Most common grade ≥3 nonhematologic TEAEs were hypoxia (54.5%), febrile neutropenia (45.5%), and hypophosphatemia (31.8%). <h3>Conclusions</h3> In patients with ICI-naive metastatic NSCLC, lifileucel plus pembrolizumab demonstrated robust antitumor activity and durable responses, including in patients with <i>EGFR</i>-wt PD-L1–negative tumors. No new safety signals were observed with lifileucel plus pembrolizumab. These results support further investigation of lifileucel/ICI combination as part of frontline therapy in metastatic NSCLC. <h3>Trial Registration</h3> NCT03645928. <h3>Ethics Approval</h3> This study was approved by the institutional review board at each site and was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines of the International Conference on Harmonization. All patients provided written informed consent.
BibTeX
@misc{creelan2024multicenter,
  author = {Ben Creelan and Kai He and Edward B. Garon and Jason Chesney and Sylvia Lee and Jorge J. Nieva and Adrian G. Sacher and Friedrich Graf Finckenstein and Brian Gastman and Jeffrey Chou and Rana Fiaz and Melissa Catlett and Guang Chen and Adam Schoenfeld},
  title = {{1488 A multicenter phase 2 trial of lifileucel plus pembrolizumab in patients with checkpoint inhibitor-naive metastatic NSCLC: updated results}},
  year = {2024},
  doi = {10.1136/jitc-2024-sitc2024.1488},
}
Figure